Cargando…

Characterization of the interferences of systemic azole antifungal drugs with adrenal steroid biosynthesis using H295R cells and enzyme activity assays

Azole antifungals, designed to inhibit fungal CYP51, have a liability to inhibit human CYP enzymes. Whilst drug-metabolizing CYPs are covered in preclinical safety assessment, those metabolizing endogenous bioactive molecules are usually not. Posaconazole and itraconazole were recently found to caus...

Descripción completa

Detalles Bibliográficos
Autores principales: Jäger, Marie-Christin, Joos, Friedrich L., Winter, Denise V., Odermatt, Alex
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10458698/
https://www.ncbi.nlm.nih.gov/pubmed/37637492
http://dx.doi.org/10.1016/j.crtox.2023.100119
_version_ 1785097228206997504
author Jäger, Marie-Christin
Joos, Friedrich L.
Winter, Denise V.
Odermatt, Alex
author_facet Jäger, Marie-Christin
Joos, Friedrich L.
Winter, Denise V.
Odermatt, Alex
author_sort Jäger, Marie-Christin
collection PubMed
description Azole antifungals, designed to inhibit fungal CYP51, have a liability to inhibit human CYP enzymes. Whilst drug-metabolizing CYPs are covered in preclinical safety assessment, those metabolizing endogenous bioactive molecules are usually not. Posaconazole and itraconazole were recently found to cause pseudohyperaldosteronism with hypokalemia and hypertension by inhibiting CYP11B1-dependent adrenal cortisol biosynthesis. Because this was overlooked in preclinical safety assessment, the present study tested whether applying adrenal carcinoma H295R cells could have predicted this liability and whether other systemic triazole antifungals interfere with adrenal steroidogenesis. Forskolin-stimulated H295R cells were exposed to systemic triazole antifungals that are currently used, and key adrenal steroids were quantified by UHPLC-MS/MS. To support the findings from the H295R model, activity assays for steroidogenic enzymes were performed. The analysis of the steroid profiles and product/substrate ratios predicted the CYP11B1 and CYP11B2 inhibition by posaconazole and itraconazole. Comparison of their steroid profiles allowed distinguishing their effects and suggested inhibition of adrenal androgen synthesis by posaconazole but not itraconazole, which was confirmed by CYP17A1 17,20-lyase activity measurements. In line with clinical observations, there was no evidence from these experiments for an inhibition of either CYP11B1/2 or CYP17A1 by voriconazole, fluconazole or isavuconazole. However, itraconazole and isavuconazole exerted an overall inhibition of steroidogenesis by a mechanism warranting further investigations. In conclusion, analyses of steroid profiles from the H295R assay and product/substrate ratios provide important information on the interference of a chemical with adrenal steroidogenesis and the underlying mechanism. This approach facilitates prioritization of further investigations, including enzyme expression and activity studies.
format Online
Article
Text
id pubmed-10458698
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-104586982023-08-27 Characterization of the interferences of systemic azole antifungal drugs with adrenal steroid biosynthesis using H295R cells and enzyme activity assays Jäger, Marie-Christin Joos, Friedrich L. Winter, Denise V. Odermatt, Alex Curr Res Toxicol Articles from the special issue on Invite 2023 edited by Thomas Knudsen Azole antifungals, designed to inhibit fungal CYP51, have a liability to inhibit human CYP enzymes. Whilst drug-metabolizing CYPs are covered in preclinical safety assessment, those metabolizing endogenous bioactive molecules are usually not. Posaconazole and itraconazole were recently found to cause pseudohyperaldosteronism with hypokalemia and hypertension by inhibiting CYP11B1-dependent adrenal cortisol biosynthesis. Because this was overlooked in preclinical safety assessment, the present study tested whether applying adrenal carcinoma H295R cells could have predicted this liability and whether other systemic triazole antifungals interfere with adrenal steroidogenesis. Forskolin-stimulated H295R cells were exposed to systemic triazole antifungals that are currently used, and key adrenal steroids were quantified by UHPLC-MS/MS. To support the findings from the H295R model, activity assays for steroidogenic enzymes were performed. The analysis of the steroid profiles and product/substrate ratios predicted the CYP11B1 and CYP11B2 inhibition by posaconazole and itraconazole. Comparison of their steroid profiles allowed distinguishing their effects and suggested inhibition of adrenal androgen synthesis by posaconazole but not itraconazole, which was confirmed by CYP17A1 17,20-lyase activity measurements. In line with clinical observations, there was no evidence from these experiments for an inhibition of either CYP11B1/2 or CYP17A1 by voriconazole, fluconazole or isavuconazole. However, itraconazole and isavuconazole exerted an overall inhibition of steroidogenesis by a mechanism warranting further investigations. In conclusion, analyses of steroid profiles from the H295R assay and product/substrate ratios provide important information on the interference of a chemical with adrenal steroidogenesis and the underlying mechanism. This approach facilitates prioritization of further investigations, including enzyme expression and activity studies. Elsevier 2023-08-14 /pmc/articles/PMC10458698/ /pubmed/37637492 http://dx.doi.org/10.1016/j.crtox.2023.100119 Text en © 2023 The Author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Articles from the special issue on Invite 2023 edited by Thomas Knudsen
Jäger, Marie-Christin
Joos, Friedrich L.
Winter, Denise V.
Odermatt, Alex
Characterization of the interferences of systemic azole antifungal drugs with adrenal steroid biosynthesis using H295R cells and enzyme activity assays
title Characterization of the interferences of systemic azole antifungal drugs with adrenal steroid biosynthesis using H295R cells and enzyme activity assays
title_full Characterization of the interferences of systemic azole antifungal drugs with adrenal steroid biosynthesis using H295R cells and enzyme activity assays
title_fullStr Characterization of the interferences of systemic azole antifungal drugs with adrenal steroid biosynthesis using H295R cells and enzyme activity assays
title_full_unstemmed Characterization of the interferences of systemic azole antifungal drugs with adrenal steroid biosynthesis using H295R cells and enzyme activity assays
title_short Characterization of the interferences of systemic azole antifungal drugs with adrenal steroid biosynthesis using H295R cells and enzyme activity assays
title_sort characterization of the interferences of systemic azole antifungal drugs with adrenal steroid biosynthesis using h295r cells and enzyme activity assays
topic Articles from the special issue on Invite 2023 edited by Thomas Knudsen
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10458698/
https://www.ncbi.nlm.nih.gov/pubmed/37637492
http://dx.doi.org/10.1016/j.crtox.2023.100119
work_keys_str_mv AT jagermariechristin characterizationoftheinterferencesofsystemicazoleantifungaldrugswithadrenalsteroidbiosynthesisusingh295rcellsandenzymeactivityassays
AT joosfriedrichl characterizationoftheinterferencesofsystemicazoleantifungaldrugswithadrenalsteroidbiosynthesisusingh295rcellsandenzymeactivityassays
AT winterdenisev characterizationoftheinterferencesofsystemicazoleantifungaldrugswithadrenalsteroidbiosynthesisusingh295rcellsandenzymeactivityassays
AT odermattalex characterizationoftheinterferencesofsystemicazoleantifungaldrugswithadrenalsteroidbiosynthesisusingh295rcellsandenzymeactivityassays